CO2021003608A2 - Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de estos - Google Patents

Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de estos

Info

Publication number
CO2021003608A2
CO2021003608A2 CONC2021/0003608A CO2021003608A CO2021003608A2 CO 2021003608 A2 CO2021003608 A2 CO 2021003608A2 CO 2021003608 A CO2021003608 A CO 2021003608A CO 2021003608 A2 CO2021003608 A2 CO 2021003608A2
Authority
CO
Colombia
Prior art keywords
epsilon
fcer1a
bind
alpha
binding molecules
Prior art date
Application number
CONC2021/0003608A
Other languages
English (en)
Spanish (es)
Inventor
Andrew J Murphy
Jamie M Orengo
Andre Limnander
Jee H Kim
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2021003608A2 publication Critical patent/CO2021003608A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CONC2021/0003608A 2018-08-23 2021-03-19 Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de estos CO2021003608A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862721921P 2018-08-23 2018-08-23
PCT/US2019/047601 WO2020041537A1 (en) 2018-08-23 2019-08-22 Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof

Publications (1)

Publication Number Publication Date
CO2021003608A2 true CO2021003608A2 (es) 2021-04-30

Family

ID=67876086

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0003608A CO2021003608A2 (es) 2018-08-23 2021-03-19 Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de estos

Country Status (18)

Country Link
US (2) US11578127B2 (cg-RX-API-DMAC7.html)
EP (1) EP3840841A1 (cg-RX-API-DMAC7.html)
JP (2) JP7402223B2 (cg-RX-API-DMAC7.html)
KR (1) KR102977145B1 (cg-RX-API-DMAC7.html)
CN (1) CN112888482B (cg-RX-API-DMAC7.html)
AU (1) AU2019325565B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021003023A2 (cg-RX-API-DMAC7.html)
CA (1) CA3109513A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021000437A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003608A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190601A1 (cg-RX-API-DMAC7.html)
IL (1) IL280745B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002165A (cg-RX-API-DMAC7.html)
MY (1) MY204368A (cg-RX-API-DMAC7.html)
PH (1) PH12021550322A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101608XA (cg-RX-API-DMAC7.html)
WO (1) WO2020041537A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100919B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021002165A (es) 2018-08-23 2021-07-16 Regeneron Pharma Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos.
US20230056380A1 (en) * 2020-01-31 2023-02-23 Randy Leiman Allen Methods and kit for detection of analytes
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
NZ553118A (en) * 2004-09-02 2009-12-24 Genentech Inc Anti-FC-gamma RIIB receptor antibody and uses therefor
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
WO2012142286A1 (en) * 2011-04-12 2012-10-18 University Of Cincinnati Methods for suppressing allergic reactions
WO2012169741A2 (ko) 2011-06-07 2012-12-13 (주)네오팜 FcεRI 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
CN104293738A (zh) 2013-09-11 2015-01-21 李莉 一种抗人FcεRⅠα亚基单克隆抗体及其应用
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
EA035269B1 (ru) 2014-08-13 2020-05-22 Зуппремоль Гмбх АНТИТЕЛО, НАПРАВЛЕННОЕ НА Fc-ГАММА-РЕЦЕПТОР IIB И Fc-ЭПСИЛОН-РЕЦЕПТОР
CN104800164B (zh) 2015-04-13 2017-11-07 上海市第一人民医院 一种雷公藤免疫纳米粒及用途
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
KR102531251B1 (ko) * 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
MX2021002165A (es) 2018-08-23 2021-07-16 Regeneron Pharma Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos.

Also Published As

Publication number Publication date
JP2023171909A (ja) 2023-12-05
EA202190601A1 (ru) 2021-07-14
IL280745B2 (en) 2026-06-01
KR102977145B1 (ko) 2026-06-12
JP7402223B2 (ja) 2023-12-20
US20230331845A1 (en) 2023-10-19
EP3840841A1 (en) 2021-06-30
IL280745A (en) 2021-04-29
PH12021550322A1 (en) 2021-10-04
US12441797B2 (en) 2025-10-14
US11578127B2 (en) 2023-02-14
WO2020041537A1 (en) 2020-02-27
KR20210049863A (ko) 2021-05-06
WO2020041537A8 (en) 2020-09-10
JP7541167B2 (ja) 2024-08-27
MY204368A (en) 2024-08-26
CA3109513A1 (en) 2020-02-27
BR112021003023A2 (pt) 2021-05-11
ZA202100919B (en) 2025-10-29
CL2021000437A1 (es) 2021-09-03
CL2023000442A1 (es) 2023-11-24
NZ772900A (en) 2025-05-02
US20200062844A1 (en) 2020-02-27
SG11202101608XA (en) 2021-03-30
AU2019325565A1 (en) 2021-03-11
AU2019325565B2 (en) 2025-09-04
CN112888482B (zh) 2024-06-25
IL280745B1 (en) 2026-02-01
CN112888482A (zh) 2021-06-01
MX2021002165A (es) 2021-07-16
JP2021533806A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
CL2021000131A1 (es) Anticuerpos anti-bcma x anti-cd3 biespecíficos y usos de estos.
CL2023000442A1 (es) Anticuerpos y fragmentos de unión a antígeno específicos para fcer1a, y sus usos
CL2021001573A1 (es) Anticuerpos anti-muc16 x anti-cd28 biespecíficos y usos de estos.
CO2019000372A2 (es) Anticuerpos contra proteína 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
CL2020003285A1 (es) Anticuerpos anti-psma x anti-cd28 biespecificos y usos de estos.
CL2019000738A1 (es) Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos.
CL2020002305A1 (es) Uso de anticuerpos sirpa v1 antihumanos y procedimiento de producción de anticuerpos anti-sirpa v1
MX2019003326A (es) Anticuerpos anti-muc16-cd3 biespecificos y conjugados anti-muc16-farmaco.
NI202000051A (es) Anticuerpos monoclonales y métodos para utilizar los mismos.
CR20200450A (es) Anticuerpos anti-trem-l y usos de los mismos
UY35042A (es) Anticuerpos anti-cd3, moléculas de unión a antígeno biespecíficas que se unen a cd3 y cd20, y usos de los mismos.
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
MX2017007744A (es) Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmumorreceptor (tigit).
MX2020013122A (es) Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47).
CO2021009689A2 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso.
ECSP22015044A (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
CO2021008204A2 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso
MX2020006155A (es) Moleculas de union a cd-16 biespecificas y su uso en el tratamiento de enfermedades.
DOP2024000117A (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
AR114129A1 (es) ANTICUERPOS TERAPÉUTICOS DIRIGIDOS CONTRA sPLA2-GIB Y SUS USOS
UY37914A (es) Anticuerpo monoclonal contr il-5r
CL2025002685A1 (es) Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso.
CO2025013101A2 (es) Anticuerpos multiespecíficos anti–cd3 y métodos de uso
CL2025002693A1 (es) Anticuerpos multiespecíficos anti-cd3 y métodos de uso.